Kenneth Galbraith

Kenneth Galbraith

Executive in Residence

Ken is Executive in Residence at Syncona Investment Management Ltd.

Ken has over 30 years’ experience in biotechnology and venture capital having worked as a life sciences executive, director, investor and advisor across North America in the growth of both private and NASDAQ-listed companies from an early-stage through commercialisation. He was the Chief Financial Officer at QLT, Canada’s first biotechnology company until 2000.

Ken has almost a decade of experience in the management of venture capital funds and new company formation and has worked with many biotechnology companies including: Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, and Aquinox among others.

Martin Murphy

Martin Murphy

Chief Executive Officer
Chris Hollowood

Chris Hollowood

Chief Investment Officer
Markus John

Markus John

Chief Medical Officer and Head of R&D
Freddie Dear

Freddie Dear

Partner
Elisa Petris

Elisa Petris

Partner
Alice Renard

Alice Renard

Partner